使用定量差异算法评估人工肝脏支持对急性至慢性肝衰竭的影响:回顾性研究
Tinghuai Huang1, Jianwei Huang2, Timon Cheng-Yi Liu1
1School of Physical Education and Sports Science, South China Normal University, Guangzhou, China.
JMIR formative research
|October 24, 2023
概括
定量差异 (QD) 算法对评估急性与慢性肝衰竭 (ACLF) 的预后显示出希望. 它的性能与末期肝病模型 (MELD) 相似,但提供了更全面的评估.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 医学预测 医学预测
- 生物标志物发现发现
背景情况:
- 由于高死亡率和成本,急性至慢性肝衰竭 (ACLF) 构成了重大挑战.
- 在整个ACLF治疗过程中,预后评估至关重要.
- 定量差异 (QD) 算法是一种改进ACLF预后评估的新工具.
研究的目的:
- 为了比较QD算法的有效性与ACLF预后的已建立的末期肝病模型 (MELD) 评分.
- 为了确定QD算法是否提供比MELD.优越或可比性能.
主要方法:
- 一组27名ACLF患者被分为常规治疗 (n=12) 和双等离子体分子吸收系统 (DPMAS) 加上常规治疗 (n=15) 组.
- 预后使用MELD和QD分数系统进行评估.
- 分析了治疗结果和特定的临床标志物.
主要成果:
- QD算法显示肝酶和胆红素的显著降低,与治疗效果相关.
- 在MELD和QD值之间发现了显著的关联 (P<.001).
- 该QD算法表明患者疲劳的改善,并显示了动态评估能力.
结论:
- QD评分系统有效地评估了ACLF患者的治疗效果,类似于MELD.
- QD算法通过整合更广泛的指标和考虑个体患者的变化来超越MELD.
- QD为ACLF预后提供了一种动态和全面的方法.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...


